OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

OBI Pharma: An Exciting Launching Pad for Young Scientists

OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

Vision: OBI Presents a Five-Year Strategic Plan

OBI Shares Opportunities and Challenges of ADC Development at BioAsia2024

OBI 's ADC Technology Platform GlycOBI® and Enzyme EndoSymeOBI® Two Trademarks Approved by Taiwan Intellectual Property Office

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation 

OBI 's Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.